Stem Cell Clinic

Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025

By Induced Pluripotent Stem Cells

NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, today announced that the Company will release financial results for its third quarter fiscal 2025 ended February 28, 2025 before financial markets open on April 8, 2025.

Visit link:
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

By Induced Pluripotent Stem Cells

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.

See the original post here:
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

By Induced Pluripotent Stem Cells

PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczac?ba??-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.

See original here:
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!

By Induced Pluripotent Stem Cells

TALLMADGE, Ohio, March 28, 2025 (GLOBE NEWSWIRE) -- ProvaDent is precisely fabricated to support oral health by promoting a balanced oral microbiome. It works to encourage the growth of beneficial bacteria while reducing harmful ones. Maintaining this balance helps protect against common oral health issues such as cavities, gum diseases, and bad breath. Supporting the oral microbiome is the key to fostering long-term oral health.

Go here to read the rest:
ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!

←